Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Mizell

Clinical Nurse Specialist, Family Health Montgomery, TX Nurse Practitioner

NPI 1457892648 CMS profile 10602440

21300 Eva St Ste 100, Montgomery, TX 77356

Open in the dashboard

General payments

$9,294

561 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Mizell of Montgomery, TX is reported in the CMS Open Payments database as having received $9,294 across 561 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Clinical Nurse Specialist, Family Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,179 122
2024 General $1,943 110
2023 General $1,858 125
2022 General $1,000 63
2021 General $2,316 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Mizell
  • Clinical Nurse Specialist, Family Health median
  • Middle half of Clinical Nurse Specialist, Family Health
  • National median

In program year 2025, general payments to Laura Mizell were reported at $2,179. Among 164 Clinical Nurse Specialist, Family Health profiles paid that year, the median was $216 and the middle half received between $57 and $492.

Show as a table
Year Laura Mizell Clinical Nurse Specialist, Family Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,316 $151 $46–$400 $132
2022 $1,000 $153 $37–$527 $149
2023 $1,858 $139 $50–$451 $160
2024 $1,943 $150 $46–$571 $164
2025 $2,179 $216 $57–$492 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,525 104 payments
  2. AstraZeneca Pharmaceuticals LP $920 52 payments
  3. Lilly USA, LLC $822 68 payments
  4. GlaxoSmithKline, LLC. $686 39 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $656 37 payments
  6. Pfizer Inc. $644 30 payments
  7. Sumitomo Pharma America, Inc. $398 25 payments
  8. AbbVie, Inc. $348 27 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $323 16 payments
  10. Amgen Inc. $289 17 payments
  11. Other $2,681 146 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,294 561 payments
Products named General payments · program years 2021–2025
  1. Ozempic $860 65 payments
  2. RYBELSUS $742 60 payments
  3. Wegovy $531 30 payments
  4. FARXIGA $491 25 payments
  5. GEMTESA $398 25 payments
  6. TRELEGY ELLIPTA $392 23 payments
  7. MOUNJARO $367 33 payments
  8. JARDIANCE $362 28 payments
  9. BREZTRI $343 19 payments
  10. NURTEC ODT $327 14 payments
  11. Other $7,153 403 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

1,943

Median for Nurse Practitioner: 389

Drug cost

$44,142

Median for Nurse Practitioner: $21,885

Branded share of claims

24%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 16 $22,479
Paxlovid Nirmatrelvir/Ritonavir Brand 33 $2,859
Levothyroxine Sodium Generic 131 $1,137
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 103 $1,071
Synthroid Levothyroxine Sodium Brand 11 $989
Doxycycline Hyclate Generic 105 $894
Ventolin Hfa Albuterol Sulfate Brand 15 $835
Methylprednisolone Generic 112 $825
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 59 $817
Nystatin Generic 32 $748

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$49,444

Of which drugs: $1,614

Medicare patients

536

Average age 76

Services billed

5,455

347 women, 189 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 28%
Diabetes 22%
Depression 20%
Atrial fibrillation 19%
Cancer 17%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 14 14 $1,098
Injection, methylprednisolone acetate, 1 mg J1010 Office 35 4,200 $385

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $113
  • Lilly USA, LLC $70
$183 16 —
GEMTESA
  • Sumitomo Pharma America, Inc. $156
$156 — —
Wegovy
  • Novo Nordisk Inc $146
$146 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $119
$119 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

561 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Family Health in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record